AGC5201
5201 logo
Fair Value
JP¥7.29k
Share price04 Aug
JP¥5.79k20.6% undervalued intrinsic discount
Loading
1Y26.41%
7D-3.16%

5201: Panel Manufacturing Advances And Steady Metrics Will Shape Market Direction

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
03 Aug 25
Updated
04 Aug 26
Views
111
Not Invested

Last Update 04 Aug 26

Fair value Decreased 4.11%

5201: Circular Fluorine Progress Under AGC Plus 2026 Will Drive Future Upside

Analysts have trimmed their price target for AGC to ¥7,286 from ¥7,599, citing updated assumptions around the discount rate, revenue growth, profit margins, and future P/E that slightly soften the stock's implied fair value.

What’s in the News for AGC

  • AGC Inc. completed third party verification based on UL 2809 in May 2026 for fluorine raw materials used in AFLAS FFKM, confirming that 100% of the fluorine content allocated under a mass balance approach comes from recycled fluorite. Source: Company key developments
  • AFLAS FFKM, an industrial elastomer used widely in semiconductor manufacturing for high reliability sealing materials and O-rings, is now prepared to be offered as a product that combines high performance with environmental considerations using Recycled Circular Fluorite. Source: Company key developments
  • Under its AGC plus 2026 mid term management plan, AGC is emphasizing deepening of sustainability management and is working toward a circular economy for fluorine resources, with approximately 73% of AFLAS FFKM polymer composition coming from fluorine that is managed as 100% recycled under the mass balance approach. Source: Company key developments
  • AGC Biologics joined OTXL’s Orphan ClinDevNet as a manufacturing partner, which expands their existing collaboration and supports development of cell and gene therapies for ultra rare conditions through coordinated end to end manufacturing. Source: Company key developments
  • Through Orphan ClinDevNet, AGC Biologics expects to help address challenges such as late stage clinical trial costs, manufacturing continuity, and geographic reach for therapies serving very small and dispersed patient populations. Source: Company key developments

Valuation Changes for AGC

  • Fair Value Estimate: the implied fair value for AGC has softened slightly to ¥7,286 from ¥7,599.
  • Discount Rate: the discount rate used in the model has risen modestly to about 7.92% from about 7.64%.
  • Revenue Growth: the assumed long term revenue growth rate is broadly steady at about 3.94% compared with about 3.91% previously.
  • Net Profit Margin: the projected net profit margin has eased slightly to about 5.07% from about 5.14%.
  • Future P/E: the future P/E multiple applied in the framework has been trimmed to about 16.25x from about 16.61x.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Advancements in product offerings, manufacturing expansion, and strategic exits are set to improve AGC's margins, profitability, and growth capacity across core business segments.
  • Rising global demand for energy-efficient and technologically advanced glass, driven by regulations and urbanization, provides sustained tailwinds for long-term revenue and earnings growth.
  • Weak demand, pricing pressures, challenging profitability in new ventures, and high capital intensity threaten AGC's revenue growth, margins, and investor confidence.

Catalysts

About AGC
    Manufactures and sells glass, electronics, chemicals, automotive, and ceramics worldwide.
What are the underlying business or industry changes driving this perspective?
  • The company is poised to benefit from a medium-term demand recovery in architectural glass, supported by increasing requirements for energy-efficient renovations in Japan and a likely rebound in Asian markets, which should drive higher shipment volumes and improved pricing, positively impacting revenue and operating profit.
  • AGC is advancing product mix upgrades in automotive and electronics (including smart technologies and value-added glass), leveraging R&D investments and pricing policies that are already beginning to yield better margins and are expected to enhance both gross and net margins over the coming cycles.
  • Expanded production capacity in Southeast Asia, especially in Chemicals (chlor-alkali, PVC), positions AGC to capture greater market share in regions with structural supply constraints, supporting higher top-line growth and scale-driven margin expansion.
  • Structural reforms and the strategic exit from loss-making U.S. biopharmaceutical operations will eliminate a major drag on profits, while refocusing Life Science on high-growth, single-use bag (SUB) technologies is expected to restore segment profitability and drive new growth from 2026 onward, directly benefitting net income.
  • Continued global trends toward sustainable, resilient construction and increased demand for advanced glass in smart, energy-efficient, and climate-adaptive buildings (driven by tighter regulations and urbanization in emerging markets) offer a structural tailwind to AGC's core businesses, underpinning long-term growth in both revenue and earnings.
AGC Earnings and Revenue Growth

AGC Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming AGC's revenue will grow by 3.9% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 4.1% today to 5.1% in 3 years time.
  • Analysts expect earnings to reach ¥119.5 billion (and earnings per share of ¥562.9) by about August 2029, up from ¥85.4 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as ¥137.4 billion.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.3x on those 2029 earnings, up from 13.9x today. This future PE is greater than the current PE for the JP Building industry at 12.5x.
  • Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.92%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Persistent weakness in demand and falling prices for key products, especially in the Asia region for architectural glass and for PVC in the Chemicals segment, due to factors like economic downturn in Europe and excess supply from China, will continue to pressure AGC's revenues and operating profit.
  • Structural and recurring losses in the Life Science/biopharmaceutical CDMO business-including unresolved production issues and heavy reliance on small and early-stage biotech clients-suggest ongoing challenges with profitability and cash flow in what is intended to be a future growth pillar.
  • Continued underperformance versus forecast (four years of operating profit and ROE below targets, with ROE under 5%), and frequent downward revisions in segment outlooks indicate difficulty in accurately forecasting and managing business cycles, which could erode investor confidence and depress valuation multiples.
  • Heightened competition and deteriorating price environment in key markets such as Indonesia and Thailand, and in electronic materials (e.g., EUV mask blanks), threaten AGC's pricing power and market share in both traditional and advanced product categories, directly impacting future revenue growth.
  • High capital intensity and limited ability to flex costs downward during periods of weak demand (noted through slow ramp-up of capacity expansions and sluggish returns from prior investments) expose AGC to sustained margin compression and subpar returns on equity and assets.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of ¥7286.25 for AGC based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ¥8290.0, and the most bearish reporting a price target of just ¥5600.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be ¥2355.2 billion, earnings will come to ¥119.5 billion, and it would be trading on a PE ratio of 16.3x, assuming you use a discount rate of 7.9%.
  • Given the current share price of ¥5585.0, the analyst price target of ¥7286.25 is 23.3% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on AGC?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

JP¥7.29k
vs JP¥5.79k20.6% undervalued intrinsic discount
PastFuture-89b2t2015201820212024202620272029Revenue JP¥2.4tEarnings JP¥119.5b
3.9%
Revenue growth
5.1%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on AGC

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet and undervalued.

Market capJP¥1.2t
PB0.8x
Estimated Growth2.6%
Dividend Yield3.6%
Full analysis

CEO & management

Yoshinori Hirai
CEO
4.8yrs
CEO Tenure

Manufactures and sells architectural glass, electronics, chemicals, automotive, and ceramics worldwide.